Aditxt Announces Closing of $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
RICHMOND, Va.–(BUSINESS WIRE)–Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and…
Year: 2023
Intellinetics to Participate at 2023 MSBO Annual Conference & Exhibit Show
Helping school districts mitigate ransomware attacks and improve records request compliance. COLUMBUS, Ohio–(BUSINESS WIRE)–Intellinetics, Inc….
A New Herbal Medicine by Sao Thai Duong JSC SUNKOVIR Effectively Treats Covid-19, Flu, and Diseases Caused by Respiratory Virus
100% OF PATIENTS SAW NO INCREASE IN LEVEL OF SEVERITY, QUICK DECREASE IN SYMPTOMS AFTER…
A New Herbal Medicine by Sao Thai Duong JSC SUNKOVIR Effectively Treats Covid-19, Flu, and Diseases Caused by Respiratory Virus
100% OF PATIENTS SAW NO INCREASE IN LEVEL OF SEVERITY, QUICK DECREASE IN SYMPTOMS AFTER…
NFL Biosciences: 2022 full-year business and earnings update
NFL Biosciences: 2022 full-year business and earnings update Phase II/III clinical trial for the drug…
NFL Biosciences: 2022 full-year business and earnings update
NFL Biosciences: 2022 full-year business and earnings update Phase II/III clinical trial for the drug…
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
LONDON and NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO;…
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
LONDON and NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO;…
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA)…
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA)…
Statement re: Further NHS Accreditation
DXS INTERNATIONAL PLC (AQSE: DXSP) Statement Re: Further NHS Accreditation DXS International, the digital clinical…
Statement re: Further NHS Accreditation
DXS INTERNATIONAL PLC (AQSE: DXSP) Statement Re: Further NHS Accreditation DXS International, the digital clinical…
Mithra Releases Invitation to its General Shareholders’ Meeting
Mithra Releases Invitation to its General Shareholders’ Meeting Liege, Belgium, 25 April 2023 – 7:30…
Mithra Releases Invitation to its General Shareholders’ Meeting
Mithra Releases Invitation to its General Shareholders’ Meeting Liege, Belgium, 25 April 2023 – 7:30…
Ultimovacs provides updated guidance on timeline for readout of INITIUM Phase II clinical trial of UV1 in malignant melanoma
It is taking longer than estimated for the patients in the INITIUM study to experience…
Ultimovacs provides updated guidance on timeline for readout of INITIUM Phase II clinical trial of UV1 in malignant melanoma
It is taking longer than estimated for the patients in the INITIUM study to experience…
Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance
Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD)…
Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance
Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD)…
Idorsia announces financial results for the first quarter 2023 – QUVIVIQ now the leading branded insomnia medicine in the commercial market in the US
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 25, 2023 Idorsia…
Idorsia announces financial results for the first quarter 2023 – QUVIVIQ now the leading branded insomnia medicine in the commercial market in the US
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 25, 2023 Idorsia…